BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 33247317)

  • 1. Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008-2018, and perspectives on cancer prevention.
    Du J; Ährlund-Richter A; Näsman A; Dalianis T
    Arch Gynecol Obstet; 2021 Feb; 303(2):329-335. PubMed ID: 33247317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine.
    Ährlund-Richter A; Cheng L; Hu YOO; Svensson M; Pennhag AAL; Ursu RG; Haeggblom L; Grün N; Ramqvist T; Engstrand L; Dalianis T; Du J
    Front Cell Infect Microbiol; 2019; 9():59. PubMed ID: 30949454
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of HPV vaccination with Gardasil® in Switzerland.
    Jacot-Guillarmod M; Pasquier J; Greub G; Bongiovanni M; Achtari C; Sahli R
    BMC Infect Dis; 2017 Dec; 17(1):790. PubMed ID: 29273004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
    Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
    Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UK population based study to predict impact of HPV vaccination.
    Hibbitts S; Tristram A; Beer H; McRea J; Rose B; Hauke A; Nuttall D; Dallimore N; Newcombe RG; Fiander A
    J Clin Virol; 2014 Feb; 59(2):109-14. PubMed ID: 24388208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papilloma virus vaccination in Nepal: an initial experience in Nepal.
    Singh Y; Shah A; Singh M; Verma S; Shrestha BM; Vaidya P; Nakarmi RP; Shrestha SB
    Asian Pac J Cancer Prev; 2010; 11(3):615-7. PubMed ID: 21039025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013.
    Ladner J; Besson MH; Rodrigues M; Audureau E; Saba J
    BMC Public Health; 2014 Jun; 14():670. PubMed ID: 24981818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
    Kann H; Hortlund M; Eklund C; Dillner J; Faust H
    Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs.
    Dillner J; Nygård M; Munk C; Hortlund M; Hansen BT; Lagheden C; Liaw KL; Kjaer SK
    Vaccine; 2018 Jun; 36(26):3820-3829. PubMed ID: 29778519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The GARDASIL vaccine can prevent cervical carcinoma caused by human papilloma virus (HPV) (results from our participation and from the study carried out in Greece).
    Ansstasiou-Fotaki P; Deligeoroglou E; Kreatsas G
    Akush Ginekol (Sofiia); 2007; 46(3):17-20. PubMed ID: 18018777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papilloma virus prevalence, genotype distribution, and pattern of infection in Thai women.
    Suthipintawong C; Siriaunkgul S; Tungsinmunkong K; Pientong C; Ekalaksananan T; Karalak A; Kleebkaow P; Vinyuvat S; Triratanachat S; Khunamornpong S; Chongsuwanich T
    Asian Pac J Cancer Prev; 2011; 12(4):853-6. PubMed ID: 21790214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology and prevention of Human Papillomavirus.
    Manini I; Montomoli E
    Ann Ig; 2018; 30(4 Supple 1):28-32. PubMed ID: 30062377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine and Non-Vaccine HPV Types Presence in Adolescents with Vertically Acquired HIV Five Years Post Gardasil Quadrivalent Vaccination: The ZIMGARD Cohort.
    Murahwa AT; Mudzviti T; Mandishora RSD; Chatindo T; Chanetsa P; Pascoe M; Shamu T; Basera W; Luethy R; Williamson AL
    Viruses; 2024 Jan; 16(1):. PubMed ID: 38275972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer.
    Arroyo Mühr LS; Gini A; Yilmaz E; Hassan SS; Lagheden C; Hultin E; Garcia Serrano A; Ure AE; Andersson H; Merino R; Elfström KM; Baussano I; Dillner J
    Nat Commun; 2024 May; 15(1):3679. PubMed ID: 38693149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
    Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
    BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.